Low direct cytotoxicity and cytoprotective effects of nitric oxide releasing indomethacin

Digestive Diseases and Sciences

Volumn 50, Issue 10, 2005, Pages 1927-1937

  Tomisato, Wataru ^a,b   Tanaka, Ken Ichiro ^a   Tsutsumi, Shinji ^a   Hoshino, Tatsuya ^a   Yokomizo, Kazumi ^a   Suzuki, Keitarou ^a   Katsu, Takashi ^b   Mizushima, Tohru ^a,a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase; Direct cytotoxicity; Gastric lesion; Indomethacin; NO NSAID; Selective cyclooxygenase 2 inhibitor

Indexed keywords

CELECOXIB; GUANYLATE CYCLASE; GUANYLATE CYCLASE INHIBITOR; INDOMETACIN; NCX 530; NITRIC OXIDE DONOR; NITRIC OXIDE INDOMETHACIN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; CYTOTOXICITY; DRUG EFFECT; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH LESION; STOMACH MUCOSA;

ACETATES; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL CULTURE TECHNIQUES; CELL DEATH; CELL SURVIVAL; CYTOPROTECTION; GASTRIC MUCOSA; GUINEA PIGS; INDOLES; INDOMETHACIN; MALE; RATS; RATS, WISTAR; STOMACH;

EID: 26244432445     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2963-4     Document Type: Article

References (47)

1. Smalley WE, Ray WA, Daugherty JR, Griffin MR: Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 141:539-545, 1995
2. Hawkey CJ: Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 119:521-535, 2000
3. Barrier CH, Hirschowitz BI: Controversies in the detection and management of nonsteroidal antiinflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum 32:926-932, 1989
4. Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 115:787-796, 1991
5. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA: Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 96:647-655, 1989
6. Kurata JH, Abbey DE: The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol 12:260-266, 1990
7. Singh G: Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105:318-388, 1998
8. Vane JR, Botting RM: Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol (Suppl 102):9-21, 1996
9. Miller TA: Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 245:G601-G623, 1983
10. Ligumsky M, Golanska EM, Hansen DG, Kauffman GJ: Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rat. Gastroenterology 84:756-761, 1983
11. Ligumsky M, Sestieri M, Karmeli F, Zimmerman J, Okon E, Rachmilewitz D: Rectal administration of nonsteroidal antiinflammatory drugs. Effect on rat gastric ulcerogenicity and prostaglandin E2 synthesis. Gastroenterology 1245-1249, 1990
12. Lichtenberger LM: Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem Pharmacol 61:631-637, 2001
13. Lichtenberger LM, Wang ZM, Romero JJ, Ulloa C, Perez JC, Giraud MN, Barreto JC: Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1:154-158, 1995
14. Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, Macpherson A, Mahmod T, Scott D, Wrigglesworth JM, Bjarnason I: Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut 41:344-353, 1997
15. Tomisato W, Tsutsumi S, Rokutan K, Tsuchiya T, Mizushima T: NSAIDs induce both necrosis and apoptosis in guinea pig gastric mucosal cells in primary culture. Am J Physiol Gastrointest Liver Physiol 281:G1092-G1100, 2001
16. Tomisato W, Tsutsumi S, Hoshino T, Hwang HJ, Mio M, Tsuchiya T, Mizushima T: Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions. Biochem Pharmacol 67:575-585, 2004
17. Takeuchi K, Mizoguchi H, Araki H, Komoike Y, Suzuki K: Lack of gastric toxicity of nitric oxide-releasing indomethacin, NCX-530, in experimental animals. Dig Dis Sci 46:1805-1818, 2001
18. Hawkey CJ, Jones JI, Atherton CT, Skelly MM, Bebb JR, Fagerholm U, Jonzon B, Karlsson P, Bjarnason IT: Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 52:1537-1542, 2003
19. 2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 366:831-837, 2002
20. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A: Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124:600-607, 2003
21. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G: Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 107:173-179, 1994
22. Wallace JL, McKnight W, Del Soldato P, Baydoun AR, Cirino G: Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest 96:2711-2718, 1995
23. Wallace JL, Miller MJ: Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 119:512-520, 2000
24. Johal K, Hanson PJ: Opposite effects of flurbiprofen and the nitroxybutyl ester of flurbiprofen on apoptosis in cultured guinea-pig gastric mucous cells. Br J Pharmacol 130:811-818, 2000
25. Fiorucci S, Santucci L, Federici B, Antonelli E, Distrutti E, Morelli O, Renzo GD, Coata G, Cirino G, Soldato PD, Morelli A: Nitric oxide-releasing NSAIDs inhibit interleukin-1beta converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNFalpha. Aliment Pharmacol Ther 13:421-435, 1999
26. Hirakawa T, Rokutan K, Nikawa T, Kishi K: Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology 111:345-357, 1996
27. Tomisato W, Takahashi N, Komoto C, Rokutan K, Tsuchiya T, Mizushima T: Geranylgeranylacetone protects cultured guinea pig gastric mucosal cells from indomethacin. Dig Dis Sci 45:1674-1679, 2000
28. Tomisato W, Hoshino T, Tsutsumi S, Tsuchiya T, Mizushima T: Maturation-associated increase in sensitivity of cultured guinea pig gastric pit cells to hydrogen peroxide. Dig Dis Sci 47:2125-2133, 2002
29. Tsutsumi S, Tomisato W, Takano T, Rokutan K, Tsuchiya T, Mizushima T: Gastric irritant-induced apoptosis in guinea pig gastric mucosal cells in primary culture. Biochim Biophys Acta 1589:168-180, 2002
30. Katsu T: Application of calcein-loaded liposomes for the determination of membrane channel size. Biol Pharm Bull 22:978-980, 1999
31. New RRC: Liposomes: A Practical Approach. Oxford: IRL Press, 1990, pp 105-161.
32. Tomisato W, Tanaka K, Katsu T, Kakuta H, Sasaki K, Tsutsumi S, Hoshino T, Aburaya M, Li D, Tsuchiya T, Suzuki K, Yokomizo K, Mizushima T: Membrane permeabilization by non-steroidal anti-inflammatory drugs. Biochem Biophys Res Commun 323:1032-1039, 2004
33. Lee BS, Chen J, Angelidis C, Jurivich DA, Morimoto RI: Pharmacological modulation of heat shock factor 1 by antiinflammatory drugs results in protection against stress-induced cellular damage. Proc Natl Acad Sci USA 92:7207-7211, 1995
34. Tsutsumi S, Gotoh T, Tomisato W, Mima S, Hoshino T, Hwang HJ, Takenaka H, Tsuchiya T, Mori M, Mizushima T: Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ, 2004
35. Kim YM, Talanian RV, Billiar TR: Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem 272:31138-31148, 1997
36. Brunner F, Stessel H, Kukovetz WR: Novel guanylyl cyclase inhibitor, ODQ reveals role of nitric oxide, but not of cyclic GMP in endothelin-1 secretion. FEBS Lett 376:262-266, 1995
37. Fiorucci S, Antonelli E, Santucci L, Morelli O, Miglietti M, Federici B, Mannucci R, Del Soldato P, Morelli A: Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology 116:1089-1106, 1999
38. Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, Kalala S, Traganos F, Benardini F, del Soldato P, Kashfi K, Rigas B: NO-donating nonsteroidal antiinflammatoiy drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol 67:2197-2205, 2004
39. Mizoguchi H, Hase S, Tanaka A, Takeuchi K: Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats. Aliment Pharmacol Ther 15:257-267, 2001
40. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-959, 2001
41. Mukherjee D: Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 63:817-821, 2002
42. McAdam BF, Catella LF, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96:272-277, 1999
43. Catella LF, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, Fitzgerald GA: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289:735-741, 1999
44. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ: Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102:840-845, 2000
45. Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, Lucchesi BR: Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104:820-825, 2001
46. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ: Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 108:585-590, 2001
47. Katsu T, Kobayashi H, Hirota T, Fujita Y, Sato K, Nagai U: Structure-activity relationship of gramicidin S analogues on membrane permeability. Biochim Biophys Acta 899:159-170, 1987